Schering-Plough Makes Its Move, Snapping Up Organon For $14.4 Billion
This article was originally published in The Pink Sheet Daily
Executive Summary
After much talk of a major acquisition, Schering buys the Organon pharmaceutical and animal health business of Akzo Nobel.
You may also be interested in...
Schering Likely To Play Up Saphris' Safety In Q4 Launch
Clearance for schizophrenia and bipolar disorder in one fell swoop marks a first in the crowded class of atypical anti-psychotics.
Schering Likely To Play Up Saphris' Safety In Q4 Launch
Clearance for schizophrenia and bipolar disorder in one fell swoop marks a first in the crowded class of atypical anti-psychotics.
Schering Plough’s Antipsychotic Saphris To Face FDA Panel Review In July
FDA’s Psychopharmacologic Drugs panel will likely consider supplemental data Schering submitted in response to an FDA complete response letter issued in January.